ライフサイエンスコーパス: infected patient

1 is isolate with the clinical outcome for the infected patient.

2 is an important complication in the HIV/HBV infected patient.

3 bodies (mAbs) that target IBV NA from an IBV-infected patient.

4 ion was associated with lower viral loads in infected patients.

5 ymphocytes from antiretroviral treated HIV-1 infected patients.

6 an understanding of the antibody response in infected patients.

7 OVID-19 and in choosing proper management of infected patients.

8 d thromboembolism are frequent in SARS-CoV-2-infected patients.

9 against HDV in 12 treatment-naive HBV/HDV co-infected patients.

10 d cells derived from hepatitis C virus (HCV)-infected patients.

11 t cause lethal infections, especially in HIV-infected patients.

12 s, handling of infected livestock or care of infected patients.

13 ccf-mtDNA levels that were higher among HIV-infected patients.

14 expressed in highly permissive cells and HBV-infected patients.

15 unodeficiency virus (HIV) progression in HIV-infected patients.

16 the role of histone PTMs in chronically HBV-infected patients.

17 y facilitate the fast growth rate of UPEC in infected patients.

18 sseminated histoplasmosis, especially in HIV infected patients.

19 places an emphasis on therapeutic aspects of infected patients.

20 zid alone for preventing tuberculosis in HIV-infected patients.

21 may be a surrogate marker of GC in H. pylori-infected patients.

22 vels were significantly elevated in COVID-19-infected patients.

23 hysicians to quickly make their decision for infected patients.

24 milar rates of HCV eradication than HCV mono-infected patients.

25 ALF occurs in 0.1%-0.5% of infected patients.

26 rs for early identification and isolation of infected patients.

27 f the world, due to migration of chronically infected patients.

28 mbled what is typically observed in Brucella-infected patients.

29 t-associated adverse reactions in loiasis co-infected patients.

30 vaccines or antiviral drugs for treatment of infected patients.

31 eminated disease is especially common in HIV-infected patients.

32 cially in human immunodeficiency virus (HIV)-infected patients.

33 eported following measles vaccination in HIV-infected patients.

34 future therapeutic approaches to treat SFTSV-infected patients.

35 in AFB microscopy smear negative PTB-HIV co-infected patients.

36 d CD69 upregulation on stimulation among HIV-infected patients.

37 , however, continue to be a major problem in infected patients.

38 halitis (MIBE) was identified in several HIV-infected patients.

39 gy-oncology, solid organ transplant, and HIV-infected patients.

40 he development of liver cancer in S. mansoni-infected patients.

41 order to adequately treat and diagnose such infected patients.

42 This approach has not been validated in HIV-infected patients.

43 ses robust innate immune activation in virus-infected patients.

44 e valuable information to more rapidly treat infected patients.

45 dy (nAb) response in clinical cohorts of HCV-infected patients.

46 dicated to investigate treatment response in infected patients.

47 e recognition between ZIKV-infected and DENV-infected patients.

48 xacerbated neurocognitive dysfunction in HIV-infected patients.

49 fibrosis/cirrhosis in a cohort of Greek HIV-infected patients.

50 ECH clears HIV-1 in blood samples from HIV-1-infected patients.

51 t cancer, cholangiocarcinoma, in chronically infected patients.

52 iated with increased incidence of NHL in HIV-infected patients.

53 mily Filoviridae and cause high lethality in infected patients.

54 iagnosis and management of these chronically infected patients.

55 major cause of disease severity and death in infected patients.

56 flammation and neurological disorders in HIV-infected patients.

57 levated production of HERV-K proteins in HIV-infected patients.

58 cytokine profiles in two distinct cohorts of infected patients.

59 V-1 Rev-mediated expression of HERV-K in HIV-infected patients.

60 increased HERV-K expression observed in HIV-infected patients.

61 ARS-CoV-2 infection in vitro and in COVID-19-infected patients.

62 yellow fever viruses in plasma samples from infected patients.

63 of host responses in acute and persistently infected patients.

64 eparation of infected or symptomatic and non-infected patients.

65 eased in bronchoalveolar lavage fluid of HIV-infected patients.

66 re receptor blocking of sera from SARS-CoV-2-infected patients.

67 ibuting to elevated HERV-K expression in HIV-infected patients.

68 erapy or vaccination for other causes in HIV-infected patients.

69 target for boosting immune responses in HIV-infected patients.

70 chanically involved molecule in INS, in PUUV-infected patients.

71 ting to the development of dementia in HIV-1 infected patients.

72 flammation and neurological disorders in HIV-infected patients.

73 ytokine responses in two distinct cohorts of infected patients.

74 of ICU beds from 724 to 1381 to accommodate infected patients.

75 ex vivo study of circulating Tfh from HIV-2-infected patients.

76 protein in metabolic changes observed in HCV-infected patients.

77 ent and manage the appropriate treatment for infected patients.

78 - to 6-fold lower than in samples from CHIKV-infected patients.

79 Two cohorts of infected patients: 1) patients in the ICU with septic sh

80 Of the 301 chronically infected patients, 158 had follow-up arranged (52%), of

81 uninfected patients (3-19 years), and 25 HIV-infected patients (3-19 years) using multiparametric flo

82 A total of 1092 HIV-infected patients (51% coinfected with hepatitis C virus

83 Conclusion: In HCV-infected patients, 6 and 8 weeks of treatment with JNJ-4

84 Of 885 chronically infected patients, 92.2% received their RNA-positive res

85 genetic evolution of M. avium in chronically infected patients, accompanied by changes in the virulen

86 to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regar

87 Six hundred eighty-two HIV-infected patients admitted to Khayelitsha Hospital, Sout

88 NA in liver biopsies from 56 chronically HBV infected patients after 3 to 5 years of telbivudine trea

89 patitis B (HBV)/hepatitis C virus (HCV) dual-infected patients after anti-HCV therapy.

90 JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to <=24 months.

91 nical Oncology advocate the inclusion of HIV-infected patients alongside HIV- patients in cancer clin

92 antly among IgM(+) memory B cells of all HCV-infected patients analyzed.

93 ripheral blood B cells of 30 MC-negative HCV-infected patients and 15 healthy controls revealed that

94 Overall, 1,253 HCV mono-infected patients and 175 HIV/HCV co-infected patients w

95 Twenty-two HIV-infected patients and 20 non-HIV-infected patients were

96 V-1 acquisition to-date, consisting of 6,334 infected patients and 7,247 population controls, to adva

97 rted PC from biopsy specimens of chronically infected patients and analyzed them with respect to thei

98 ms, including circulating rings from malaria-infected patients and artemisinin-induced quiescent para

99 analyses identified a diverse set strains in infected patients and asymptomatic carriers.

100 rgan failure, are now affecting thousands of infected patients and causing widespread mortality.

101 ll-free mitochondrial DNA (ccf-mtDNA) in HIV-infected patients and controls.

102 In contrast, infected patients and ferrets exhibit large changes in b

103 se of cancer morbidity and mortality for HIV-infected patients and have increased incidence even in p

104 he heterogeneity of viral dynamics in dengue-infected patients and its precise treatment are still un

105 level was higher in the liver tissue of HBV-infected patients and mice.

106 onfirmed coronavirus disease 2019 (COVID-19)-infected patients and specificity using 1,204 samples su

107 treatment of lymphoma is now similar for HIV-infected patients and the general population: patients w

108 his study, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed.

109 d visitors, actively monitor for potentially infected patients, and implement appropriate infection p

110 oach to study parasite dynamics in naturally-infected patients, and is a significant improvement on t

111 Tobacco smoking is common in HIV-infected patients, and is prevalent among intravenous op

112 nce of venous thromboembolism is 1.5-3.4% of infected patients, and it occurs due to a hypercoagulabl

113 olonized and/or infected) and the outcome of infected patients, and monitored the environmental occur

114 All candidates were recognized in sera from infected patients, and readily induced antibody response

115 Laboratory diagnostics of infected patients, and the assessment of immunity agains

116 and 2 from NS1) strongly recognized by ZIKV-infected patients' antibodies were identified and were n

117 not cross-recognized by dengue virus (DENV)-infected patients' antibodies.

118 eptides were not strongly recognized by ZIKV-infected patients' antibodies.

119 nosis of ZIKV is very difficult because most infected patients are asymptomatic or display nonspecifi

120 Human immunodeficiency virus (HIV)-infected patients are at increased risk of liver-related

121 , which suggests that most deaths in ICUs in infected patients are produced by viral sepsis.

122 screening venues where 2%-10% of chronically infected patients are treated.

123 plasma and in induced skin blisters of DENV-infected patients, as well as concomitant signaling down

124 nocyte/macrophage activation) in 39 COVID-19-infected patients at hospital admission and 2 additional

125 ens were obtained from seropositive HTLV-1/2-infected patients attending the National Centre for Huma

126 to opt out of the care Covid-19 suspected or infected patients before an anticipated surge.

127 regression analyses showed that in COVID-19-infected patients both CD3(+) CD4(+) and CD3(+) CD8(+) e

128 atment initiation for newly diagnosed, HIV-1-infected patients but prospective US data are limited.

129 s are observed only in a small proportion of infected patients but the cellular mechanisms underlying

130 often detectable in VCs than in chronically infected patients, but not in healthy seronegative donor

131 dings suggest that hepatic fibrosis in HIV-1 infected patients can be modulated by the mutation of CC

132 In this prospective cohort study, 30 HIV-infected patients (CD4+ count <100 cells/uL) underwent F

133 at distinct body temperature trajectories of infected patients correlated with survival.

134 Nevertheless, few long-infected patients develop antibodies, called broadly neu

135 higher titers to both ZIKV and DENV2 in ZIKV-infected patients diagnosed with GBS compared with non-G

136 CD4 T cells from HIV-1 infected patients die at excessive rates compared to tho

137 In HCV-infected patients, disruption of the BMP6/hepcidin axis

138 in 29 HCV-infected LTx-recipients and 17 HCV-infected patients during DAA-treatment.

139 igated cellular immune responses in COVID-19-infected patients during disease but little is known reg

140 Among CMV-infected patients, each log2 increase in nAb titer was a

141 entral nervous system and cause paralysis in infected patients, especially young children and immunoc

142 ere acute respiratory syndrome coronavirus 2 infected patients, even in the absence of hypoxia.

143 pecific binding towards the blood samples of infected patients, even in the presence of 'matrix' and

144 One GT1a-infected patient experienced late viral relapse after ac

145 s (12/14), which was carried in the blood of infected patients for 10-59 days until treatment with do

146 HIV-infected patients from 2 Canadian cohorts underwent tran

147 ART-naive HIV-1-infected patients from Cameroon were subjected to a mult

148 arch databases were used to select adult HIV-infected patients from each payer.

149 HIV-infected patients from eight prospective cohorts were in

150 ate analysis was employed to distinguish HIV-infected patients from healthy uninfected controls in a

151 V genomes sampled from nonhuman primates and infected patients from the southeastern region.

152 9 isolates, primarily C. neoformans from HIV-infected patients, from 5 countries in Asia and Africa.

153 Indonesian patients and 20% of reported H5N1-infected patients globally.

154 DTG regimen in virologically suppressed HIV-infected patients >=50 years old or with a Framingham sc

155 probability weighting method on the PS, HIV-infected patients had a lower risk of HCC [powered HR=0.

156 HIV-infected patients had a significantly higher rate of SST

157 Infected patients had higher risk for death (18 vs. 8 de

158 Moreover, we found that >43% of infected patients had no serological evidence of prior i

159 that more than 80% of CD4+ T cells from HIV-infected patients have morphological abnormalities.

160 mprovements over time for both, but with HIV-infected patients having greater improvements (P-trends

161 mprovements over time for both, but with HIV-infected patients having greater improvements (P-trends=

162 826-like sequences can be identified in H7N9-infected patients, healthy adults, and newborn babies.

163 with only 50% case detection among HIV/TB co-infected patients, hence the need to determine the diagn

164 For 33 pairs of HIV-infected patients (hereafter, "index patients") and thei

165 In HIV-infected patients, higher plasma sodium was uniformly as

166 ence of antibody sequences across SARS-CoV-2-infected patients, highlighting stereotyped naive respon

167 ecognized as an important comorbidity of HIV-infected patients, however, the exact molecular mechanis

168 ity among Human Immunodeficiency virus (HIV) infected patients; however no consensus exists on HIV-re

169 (HBsAg) from the circulation of chronically infected patients (i.e., seroconversion) is usually asso

170 tion and protracted illness observed in H5N1-infected patients.IMPORTANCE Influenza viruses cause upp

171 (representative of Italian hepatitis C virus-infected patients in care).

172 This result suggests that HIV-infected patients in Guangxi maintaining a BMI of 19-28

173 lymorphisms that were overrepresented in HIV-infected patients in Japan sharing the same HLA genotype

174 enerate 649 SARS-CoV-2 genome sequences from infected patients in New Zealand with samples collected

175 n of different leukocyte subsets in COVID-19-infected patients in relation to disease severity.

176 imal second-line treatment options for HIV-1-infected patients in resource-limited settings.

177 ctions in human immunodeficiency virus (HIV)-infected patients in resource-limited settings.

178 STI incidence among HIV-infected and non-HIV-infected patients in the United States after 2010.

179 From a cohort of HBV-infected patients in Vietnam, we assessed the proportion

180 d between 20 February and 15 March 2020 from infected patients in Washington state in the United Stat

181 ancers in human immunodeficiency virus (HIV)-infected patients in Zambia.

182 direct-acting antiviral treatment-naive, gt3-infected patients, including those with rarer subtypes,

183 In HIV-infected patients initiating ART at advanced disease, th

184 contributes to mortality in hospitalized HIV-infected patients investigated for TB.

185 The diagnosis of tuberculosis (TB) in HIV-infected patients is challenging.

186 ntification of effective antivirals to treat infected patients is of the highest importance.

187 leading to profound immunodeficiency of HIV-infected patients is still only partially understood.

188 ikelihood of drug-drug interactions in HIV-1-infected patients is through the development of long-act

189 has led to better long-term outcomes in HIV infected patients, it has not been as effective at rever

190 ph nodes, where filarial nematodes reside in infected patients, leading to an effective therapy for l

191 In Zika-infected patients, levels of IL-1beta showed a significa

192 A static rate of LT among HIV-infected patients may reflect improvements in cirrhosis

193 type analyses in a cohort of HIV-1 subtype C-infected patients (n = 168), together with site-directed

194 ized trial of behavioral weight loss for HIV-infected patients (n = 40).

195 Gastric biopsies of 814 H. pylori infected patients naive for treatment were analyzed befo

196 e prospectively followed a cohort of 84 DENV-infected patients of whom 29 were coinfected with HIV un

197 ross-sectional study was conducted among HIV-infected patients on antiretroviral therapy at 20 AIDS c

198 for monitoring human immunodeficiency virus-infected patients on antiretroviral therapy.

199 a potential target for immunotherapy in HIV-infected patients on ART with insufficient immune recons

200 udy (1:1) we reviewed medical records of HIV-infected patients on cART in a referral AIDS center in S

201 interfere with their reconstitution in HIV-1-infected patients on cART.

202 ohort of HIV-HTLV-1 co-infected and HIV mono-infected patients on cART.

203 ls accumulate in the blood of aviremic HIV-1-infected patients on long-term antiretroviral therapy, a

204 ately 1 in 10(6) cells and in cells from HIV-infected patients on suppressive antiretroviral therapy

205 In 44.6% of HCV genotype 1-infected patients, only the variant rs12785878 in the DH

206 rigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection.

207 CD4(+) T-cells among influenza A/H3N2 and B-infected patients (p = 0.006 and 0.004 respectively).

208 le and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassion

209 CWs) have elevated risk of contact with EBOV-infected patients, particularly if safety precautions ar

210 of morbidity and mortality in the HBV/HIV co-infected patient population.

211 The B. burgdorferi-infected patient presented with fever, whereas the remai

212 itor, in naive and paired HIV-1/O vs HIV-1/M infected (+) patients (ratio 1:2), matched on several cr

213 Infected patients received significantly more saline flu

214 Infected patients received significantly more saline flu

215 OV) proteome was characterized in an acutely infected patient receiving supportive care alone to eluc

216 In HIV-infected patients receiving ART, chronic co-infection wi

217 HCV-infected patients receiving cancer treatment at our inst

218 (HBV)-human immunodeficiency virus (HIV) co-infected patients receiving combined antiretroviral ther

219 pplication to the number of CD4 cells of HIV-Infected patients recruited in the CAPRISA 002 Acute Inf

220 ctions in human immunodeficiency virus (HIV)-infected patients remains increased despite antiretrovir

221 ere acute respiratory syndrome coronavirus 2 infected patients, resource levels, concerns about being

222 In addition, lung metagenomic studies on infected patients revealed overrepresented Prevotella sp

223 inical Rif(R) RNAP substitution found in Mtb infected patients (S456>L of the beta subunit).

224 ne can take months up to years, detection of infected patients seems like one of the best ideas for c

225 mbrane/envelope and NS1 antibodies from ZIKV-infected patient sera, although lower cross-reactivity t

226 particles, but are the major antigens in HEV-infected patient sera.

227 should not contraindicate cancer therapy and infected patients should have access to multiple cancer

228 riological status at diagnosis among 127 HIV-infected patients starting TB treatment.

229 ty adjusted for age was higher in HIV/HCV co-infected patients (subhazard ratio [SHR] = 1.88; 95% con

230 Previous studies investigating HIV-infected patients suggested a direct link between underw

231 2C expression and disease progression in HBV-infected patients suggests a role in HBV-induced liver d

232 Of the 80 infected patients, test results for 74 (93%) would have

233 ut CDI cases are more likely linked to other infected patients than colonized patients in this cohort

234 sed by a higher frequency of NK cells in HIV-infected patients than in controls.

235 ovide potential insight for treatment of HIV-infected patients that are at risk of developing cerebro

236 In conclusion, Mpro is a potent Ag in infected patients that can be used in serological tests,

237 In avian influenza virus-infected patients, the host immune system is activated i

238 es can be detected in the lungs and blood of infected patients, the role of extra-respiratory organs

239 a robust decrease in viral RNA levels in HCV-infected patients, thereby validating our hypothesis tha

240 certain conditions may increase the risk of infected patients to develop severe COVID-19.

241 s HLA genotypes and spVL data from 6,311 HIV-infected patients to interrogate the entire HIV-1 proteo

242 cancer and elevated cancer incidence in HIV-infected patients together increase the need for detaile

243 of CCL18 levels was detected among the HIV-1-infected patients treated with combined antiretroviral t

244 CV spontaneous resolution and 21 chronically infected patients treated with directly acting antiviral

245 Among genotype 1-infected patients treated with ledipasvir/sofosbuvir mon

246 cluded studies that reported on AEs in HIV-1-infected patients undergoing TIs.

247 In P. falciparum-infected patients, Vgamma9Vdelta2 T cells presented incr

248 In contrast to chronically HIV-1-infected patients, we found that at the earliest phases

249 s bearing HCV envelope proteins from acutely infected patients, we show that HCV variants isolated pr

250 d infection, yet we observed that 82% of the infected patients were adults.

251 fic CD4+ and CD8+ T-cell responses of 32 HDV-infected patients were analyzed by enzyme-linked immunos

252 507 HIV-infected patients were divided into a training (n=318) a

253 nty-two HIV-infected patients and 20 non-HIV-infected patients were evaluated.

254 For decades, HIV-infected patients were excluded from consideration for k

255 1035 HCV-infected patients were included, 667 (64%) coinfected wi

256 his US urban setting, over two thirds of HCV-infected patients were linked to care; although treatmen

257 HIV-infected patients were significantly less accurate on th

258 P. vivax-infected patients were treated radically with chloroquin

259 P. ovale spp. infected patients were treated with artemether-lumefantr

260 loping hepatocellular carcinoma (HCC) in HCV-infected patients who achieve sustained virological resp

261 e considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have c

262 ed substitutions identified in NS3 from GT1a-infected patients who failed therapy with grazoprevir (i

263 onducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/

264 tterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response t

265 propensity score-matched cohort of 8064 HCV-infected patients who had at least a 12-month follow-up

266 A total of 192 HBV/HCV dual-infected patients who had received pegylated interferon

267 HCV treatment was highly effective among HIV-infected patients who received care within an integrated

268 mation about the clinical characteristics of infected patients who require intensive care is limited.

269 of transplanted patients, among which 7 HIV-infected patients who subsequently developed Kaposi sarc

270 of 26 critically ill hospitalized SARS-CoV-2-infected patients who underwent electroencephalography t

271 hs of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuber

272 About 30% of infected patients will develop chronic Chagas cardiomyop

273 ffness (LS) predicts clinical outcome in HIV-infected patients with active HCV coinfection, but infor

274 Among HCV-infected patients with advanced fibrosis, who achieve SV

275 Among HIV-infected patients with advanced immunosuppression, enhan

276 carcinoma (HCC) in 15,059 hepatitis C virus-infected patients with advanced liver disease defined by

277 E), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HB

278 ic inflammation and thrombosis in SARS-CoV-2-infected patients with cancer, with the concern that the

279 We identified 333 HIV-infected patients with CD4 + T-cell-counts >= 500/ul, am

280 Conclusion: In HCV-infected patients with cirrhosis, HIV co-infection was n

281 CV mono-infected patients and 175 HIV/HCV co-infected patients with cirrhosis, included in two prospe

282 lood total and memory B cells between 27 HIV-infected patients with CM who developed C-IRIS and 63 wh

283 ecommendation of a single dose of BPG in HIV-infected patients with early syphilis.

284 Selected human immunodeficiency virus (HIV)-infected patients with end organ failure can safely rece

285 wn to be safe and effective for selected HIV-infected patients with hematological malignancies.

286 ity for all patients with HF and in COVID-19-infected patients with HF.

287 bactam-fosfomycin has the potential to offer infected patients with high bacterial burdens a therapeu

288 ut susceptibility to the outcome of COVID-19-infected patients with MM.

289 egravir (RAL) on hepatic steatosis among HIV-infected patients with nonalcoholic fatty liver disease

290 HIV-infected patients with OcC have a high incidence of live

291 no effective vaccine available: treatment of infected patients with praziquantel is the mainstay of c

292 (PIB) +/- ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DA

293 ortion of human immunodeficiency virus (HIV)-infected patients with specific comorbidities receiving

294 with elevated KSHV-VL in critically ill HIV-infected patients with suspected but not microbiological

295 evaluating the LAM test in hospitalized HIV-infected patients with suspected TB.

296 Some HCV-infected patients with sustained virological response (S

297 In genotype 1 infected patients with treatment failure and 156-RASs, w

298 ) in some human immunodeficiency virus (HIV)-infected patients with underlying neoplasia or opportuni

299 onic hepatitis C virus (HCV) genotype (GT)-1-infected patients without cirrhosis and has now been eva

300 As remain expensive, so treatment of all HCV-infected patients would substantially affect health care